The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish

Ponzoni, Luisa; Braida, Daniela; Bondiolotti, Gianpietro; Sala, Mariaelvina

doi:10.3389/fpsyt.2017.00146

Cited by 7 publications

(8 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies examined ASD-specific behaviour in MDMA-treated fish, in particular social behaviour [ 103 - 106 ]. They found that when 1 or 5 mg/kg MDMA was singularly intramuscularly injected into electric fish, asocial behaviour decreased and prosocial behaviour increased [ 103 ].…”

Section: Resultsmentioning

confidence: 99%

“…This is because fish tend to become anxious towards the water’s surface as there is a greater risk of predation there [ 108 , 109 ], and shoaling behaviour is generally a result of alarm pheromones dissipated among the fish [ 104 , 110 ]. Ponzoni et al (2016, 2017) found that a singular intramuscular injection of 0.1-10 mg/kg MDMA increased social preference [ 105 , 106 ]. Two studies looked at social behaviour in singularly MDMA-immersed octopodes [ 111 , 112 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of the MDMA Model to Address Social Impairment in Autism

Chaliha

Mamo

Albrecht

et al. 2021

View full text Add to dashboard Cite

Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterised by repetitive behaviours, cognitive rigidity/inflexibility, and social-affective impairment. Unfortunately, no gold-standard treatments exist to alleviate the core socio-behavioural impairments of ASD. Meanwhile, the prosocial empathogen/entactogen 3,4- methylene-dioxy-methamphetamine (MDMA) is known to enhance sociability and empathy in both humans and animal models of psychological disorders. Objective: We review the evidence obtained from behavioural tests across the current literature, showing how MDMA can induce prosocial effects in animals and humans, where controlled experiments were able to be performed. Methods: Six electronic databases were consulted. The search strategy was tailored to each database. Only Englishlanguage papers were reviewed. Behaviours not screened in this review may have affected the core ASD behaviours studied. Molecular analogues of MDMA have not been investigated. Results: We find that the social impairments may potentially be alleviated by postnatal administration of MDMA producing prosocial behaviours in mostly the animal model. Conclusion: MDMA and/or MDMA-like molecules appear to be an effective pharmacological treatment for the social impairments of autism, at least in animal models. Notably, clinical trials based on MDMA use are now in progress. Nevertheless, larger and more extended clinical studies are warranted to prove the assumption that MDMA and MDMA-like molecules have a role in the management of the social impairments of autism.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the MDMA Model to Address Social Impairment in Autism

Chaliha

Mamo

Albrecht

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The above-mentioned AVPV 1A Rs and AVPV 1B Rs distinctions suggest that a drug-induced reward in rodents may be attenuated by the blockage of AVPV 1B Rs, whereas the blockage of AVPV 1A Rs prevents the amelioration of a drug reward. Interestingly, the SR49059-induced AVPV1ARs blockage prevented the acquisition of MDMA-CPP in adult zebrafish [ 98 ], indicating a possible species-dependent effect; however, available data are insufficient to fully confirm this hypothesis. The effects of AVP and AVPRs ligands on behavioral/rewarding effects of different drugs of abuse has been summarized in Table 3 and Table 4 , respectively.…”

Section: The Impact Of Ot/avp and Otrs/avprs Ligands On Behavioral An...mentioning

confidence: 99%

The Role of Oxytocin and Vasopressin in Drug-Induced Reward—Implications for Social and Non-Social Factors

2023

View full text Add to dashboard Cite

Drug abuse is a worldwide problem that leads to negative physical, mental, and economic consequences. Although pharmacological strategies for drug addiction management have been widely studied, therapeutic options with high efficacy and a low side-effects profile are still limited. Recently, there has been a growing interest in oxytocin (OT) and vasopressin (AVP) systems as potential therapeutic targets for the treatment of drug abuse. OT and AVP are hypothalamic neuropeptides involved in numerous physiological processes. Additionally, studies show that these neurohormones are highly implicated in the modulation of a wide range of behaviors. Interestingly, ample evidence has shown that both, OT and AVP are able to decrease the consumption of different drugs of abuse, as well as to ameliorate their rewarding and reinforcing effects. Furthermore, OT and AVP have been strongly involved in prosocial effects and social reward. In particular, OT has been shown to be able to shift drug-induced reward into social-induced reward, mainly due to its interaction with the dopaminergic system. This phenomenon is also reflected in the results of clinical trials where intranasal OT shows promising efficacy in managing substance use disorder. Therefore, the aim of this review is to comprehensively characterize the involvement of OT and AVP in the rewarding and other behavioral effects of drugs of abuse in animal models, with a particular highlight on the impact of social factors on the observed effects. Understanding this relationship may contribute to higher drug development success rates, as a result of a more profound and deliberate studies design.

show abstract

“…For pharmacological experiments with V1a agonist and antagonist, baseline measures were taken before intraperitoneal injection of the drugs. The agonist was 22,23 Measurements were obtained at 30-min intervals up to 120…”

Section: Pharmacology and Compoundsmentioning

confidence: 99%

<p>DNA Microarray Analysis of Differential Gene Expression in the Dorsal Root Ganglia of Four Different Neuropathic Pain Mouse Models</p>

Yokoyama¹,

Hirai²,

Nagata³

et al. 2020

JPR

View full text Add to dashboard Cite

Pathological stimuli or injury to the peripheral nervous system can trigger neuropathic pain with common clinical features such as allodynia and hypersensitivity. Although various studies have identified molecules or genes related to neuropathic pain, the essential components are still unclear. Therefore, in this study, we investigated the molecular and genetic factors related to neuropathic pain. Methods: We extracted candidate genes in the dorsal root ganglion (DRG) from three nerve injury mouse models and a sham-operated model (sciatic nerve ligation and resection, sural nerve resection, spared nerve injury [SNI], and sham) using DNA microarray to elucidate the genes responsible for the neuropathic pain mechanism in the SNI model, which exhibits hypersensitivity in the hindpaw of the preserved sural nerve area. We eliminated as many biases as possible. We then focused on an upregulated endogenous vasopressin receptor and clarified whether it is closely associated with traumatic neuropathic pain using a knockout mouse and drug-mediated suppression of the gene. Results: Algorithm analysis of DNA microarray results identified 50 genes significantly upregulated in the DRG of the SNI model. Two independent genes-cyclin-dependent kinase-1 (CDK-1) and arginine vasopressin receptor 1A (V1a)-were subsequently identified as candidate SNI-specific genes in the DRG by quantitative PCR analysis. Administration of V1a agonist to wild-type SNI mice significantly alleviated neuropathic pain. However, V1a knockout mice did not exhibit higher hypersensitivity to mechanical stimulation than wildtype mice. In addition, V1a knockout mice showed similar pain behaviors after SNI to wildtype mice. Conclusion: Through the DNA microarray analysis of several neuropathic models, we detected specific genes related to chronic pain. In particular, our results suggest that V1a in the DRG may partially contribute to the mechanism of neuropathic pain.

show abstract

The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish

Cited by 7 publications

References 100 publications

A Systematic Review of the MDMA Model to Address Social Impairment in Autism

A Systematic Review of the MDMA Model to Address Social Impairment in Autism

The Role of Oxytocin and Vasopressin in Drug-Induced Reward—Implications for Social and Non-Social Factors

<p>DNA Microarray Analysis of Differential Gene Expression in the Dorsal Root Ganglia of Four Different Neuropathic Pain Mouse Models</p>

Contact Info

Product

Resources

About